Brimonidine
From Wikipedia, the free encyclopedia
 |
|
|
Brimonidine
|
|
| Systematic (IUPAC) name | |
| 5-Bromo-N-(4,5-dihydro-1H-imidazol-2-yl) quinoxalin-6-amine | |
| Identifiers | |
| CAS number | |
| ATC code | S01 |
| PubChem | |
| DrugBank | |
| Chemical data | |
| Formula | C11H10BrN5 |
| Mol. mass | 292.135 g/mol |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Metabolism | liver primarily |
| Half life | 3 hours |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. |
B |
| Legal status |
unknown |
| Routes | Ocular, 1 gtt |
Brimonidine (bri-MOE-ni-deen, brand names Alphagan and Alphagan-P) is a drug used to treat open-angle glaucoma or ocular hypertension. Alphagan is also used to induce miosis for people suffering from poor night vision after Lasik or PRK surgery.
It acts via decreasing synthesis of aqueous humor, and increasing the amount that drains from the eye. As a treatment for glaucoma, it is usually given in eyedrop form.
Brimonidine is an α2-adrenergic receptor agonist.
Alpha 2 agonists, through the activation of the Gi GPCR, inhibit the production of AC. This reduces cAMP and hence Aqueous Humour production by the ciliary body.
[edit] Clinical uses
Brimonidine is indicated for the lowering of intraocular pressure in patients with open-angle glaucoma or ocular hypertension.
[edit] External links
[edit] References
- Mosby's Drug Guide for Nurses (7th edition; Skidmore) 2007.
|
||||||||||||||||||||
